investiment.io
Agios Pharmaceuticals, Inc.
$44.32
0.28 (0.63%)
Agios Pharmaceuticals, Inc.
$44.32
0.28 (0.63%)
0HB0.L Price Chart
| Basic | |
|---|---|
| Market Cap | $2.76B |
| Price | $44.32 |
| 52 Week Range | 20.13-53.4126 |
| Beta | 0.75 |
| Margins | |
| Gross Profit Margin | -171.88% |
| Operating Profit Margin | -1293.88% |
| Net Profit Margin | -1165.69% |
| Valuation (TTM) | |
| P/E Ratio | -6.90 |
| Price to Sales Ratio | 80.54 |
| Price to Book Ratio | 3.81 |
| PEG Ratio | 2.42 |
Industry
Medical - Pharmaceuticals
Sector
Healthcare
Full-Time Employees
383
Website
IPO Date
2018-01-29T00:00:00.000Z
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Phone
617 649 8600
Address
88 Sidney Street, Cambridge, MA, 02139-4169, US